drugset

drugset / Trial / NCT04162158

Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT04162158 ↗

Phase 1/2 Unknown 200 enrolled Beijing 302 Hospital Shenzhen Third People's Hospital · collab The first People's Hospital of Zhengzhou · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, paired control study to evaluate the safety and clinical efficacy of allogeneic NK cells combined with targeted drug in the treatment for advanced HCC.

Timeline

Start: 2019-03-01
Primary completion: 2022-10-01
Completion: 2024-10-01

Publications

Uong TNT, Yoon M, Chung IJ, Nam TK, Ahn SJ, Jeong JU, Song JY, Kim YH, Nguyen HPQ, Cho D, Chu TH, Dang GC, Nguyen NPNM. Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer Models. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):234-250. doi: 10.1016/j.ijrobp.2023.11.023. Epub 2023 Nov 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	allogeneic NK cells	Cell therapy	4e+09 cells	Other
Subject	allogeneic NK cells	Cell therapy	5e+09 cells	Other

Indications